BioMarin (BMRN) Says Data from Phase 1/2 '190 Study Shows Stabilization of Disease
Tweet Send to a Friend
BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced interim results from its Phase 1/2 pivotal study for BMN 190 or cerliponase ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
